Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies

• Published in: Cancer Immunology, Immunotherapy Vol. 72; no. 12; pp. 4031 - 4047
• Main Authors: Luo, Yan, Qie, Yaqing, Gadd, Martha E., Manna, Alak, Rivera-Valentin, Rocio, To, Tommy, Li, Shuhua, Yassine, Farah, Murthy, Hemant S., Dronca, Roxana, Kharfan-Dabaja, Mohamed A., Qin, Hong
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2023; Springer Nature B.V
• Subjects: Antigens, CD19; Antitumor activity; BLyS protein; Cancer Research; CD19 antigen; Cell culture; Cell proliferation; Cell therapy; Chronic lymphocytic leukemia; Cytotoxicity; Humans; Immunology; Immunotherapy, Adoptive; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - therapy; Lymphocytes; Lymphocytes B; Lymphocytes T; Lymphoma; Lymphoma - therapy; Malignancy; Medicine; Medicine & Public Health; Monoclonal antibodies; Oncology; Receptors, Chimeric Antigen; Tumor cells; Tumors; BAFF-R; CAR-T; Lymphoma; Immunotherapy; Leukemia; B-cell malignancies

Several CD19-targeting CAR-T cells are used to treat leukemias and lymphomas; however, relapsed and/or refractory (R/R) disease is still observed in a significant number of patients. Additionally, the success of CD19-CAR-T cell therapies is not uniform across hematological malignancies, particularly...